Tolmar Announces Acquisition of JATENZO (testosterone undecanoate) for the Treatment of Hypogonadism to Expand its Market Leading Urology Portfolio

Tolmar Announces Acquisition of JATENZO
Tolmar Announces Acquisition of JATENZO :
  • Launched in 2020, JATENZO was the first oral softgel testosterone medicine approved in the US by the FDA in more than 60 years
  • JATENZO is an oral softgel testosterone undecanoate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired)
  • Compelling fit with Tolmar’s strategy to acquire and develop therapies targeting diseases and conditions in Urology, Oncology and Orphan Diseases leveraging the company’s focus and commitment in Urology community and Men’s Health

Tolmar Pharmaceuticals, Inc., a fully integrated pharmaceutical company, announced today that it has acquired all of Clarus Therapeutics Holdings, Inc.’s and its wholly-owned subsidiary Clarus Therapeutics, Inc.’s rights to JATENZO®. Tolmar was chosen as the successful bidder in the sale of JATENZO (and other connected assets) after a competitive auction process, and the sale was authorised by the U.S. For the District of Delaware, bankruptcy court.

“The addition of JATENZO to Tolmar’s robust portfolio further strengthens our position as a leader in urology and men’s health”, ” We have seen tremendous success in urology through our foundational therapy, ELIGARD®, a market-leading product for advanced prostate cancer. This acquisition advances Tolmar’s overall business strategy, provides substantial growth potential and helps advance our mission to advocate for patients through our therapies. In addition, we are confident that adding JATENZO to the products promoted by our successful urology field sales force will lead to fast and more profitable growth for this differentiated product.”

Anil D’Souza, President and Chief Executive Officer of Tolmar Pharmaceuticals.


“Hypogonadism affects each man differently, and JATENZO expands treatment options for patients and HCPs by offering a differentiated alternative to existing testosterone replacement therapies. The acquisition of JATENZO is another milestone that solidifies Tolmar’s commitment to bringing forward therapies that improve healthcare experience as well as disease outcomes.”

Todd Smith, President and Chief Commercial Officer.

A testosterone prodrug that the body transforms to testosterone, testosterone undecanoate is the foundation of JATENZO’s patented formulation. A mean total testosterone concentration in the eugonadal range was attained by 87 percent of the hypogonadal males treated with JATENZO at the conclusion of the pivotal inTUne (investigational testosterone undecanoate) clinical trial. In a 4-month, open-label research, 166 adult, hypogonadal males investigated the efficacy and safety of JATENZO. The percentage of participants whose mean plasma total testosterone concentration (Cavg) throughout a 24-hour period was within the normal eugonadal range at the study’s last PK visit served as the primary objective.

For More Healthcare News Click Here

Next Post

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

INO-4800 was going to be developed as a COVID-19 heterologous booster vaccine, but INOVIO, a biotechnology company specialising in the development and commercialization of DNA medicines to help treat and prevent infectious diseases, cancer, and diseases linked to HPV, has announced today that it has stopped doing so. The choice […]
COVID-19 Heterologous Booster Vaccine